Lindbrook Capital’s Foghorn Therapeutics FHTX Stock Holding History

Lindbrook Capital’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-23	Closed	–	–	2890
2022 Q3	$0	Sell	23 -107	-82%	-$1.38K	﹤0.01%	2712
2022 Q2	$2K	Buy	+130	New	+$1.68K	﹤0.01%	1954

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lindbrook Capital's FHTX Position: Q4 2022 in Review

Lindbrook Capital sold out of Foghorn Therapeutics (FHTX) in Q4 2022, closing a stake of 23 shares.

Lindbrook Capital first reported a position in FHTX in Q2 2022 and held it in 2 quarters. The position peaked at $2K in Q2 2022. 65 funds tracked by Wall St. Rank hold FHTX as of Q4 2022.

Lindbrook Capital reported no remaining Foghorn Therapeutics position as of Q4 2022 after selling out during the quarter.
Lindbrook Capital sold 23 Foghorn Therapeutics shares in Q4 2022.
Lindbrook Capital first reported a position in Foghorn Therapeutics in Q2 2022 and held it in 2 quarters.
Lindbrook Capital's Foghorn Therapeutics position peaked at $2K in Q2 2022.
65 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2022.

Based on Lindbrook Capital's 13F filing for Q4 2022, filed 25 Jan 2023.